MIRALUMA pharmaceutical API fine chemical suppliers

Subscribe to access the full database, or Get Started Free
Vendor	Vendor Homepage	Vendor Sku	API Url
BenchChem	⤷ Get Started Free	B1197983	⤷ Get Started Free
>Vendor	>Vendor Homepage	>Vendor Sku	>API Url

Last updated: July 29, 2025

Introduction

MIRALUMA (miransertib) is an experimental oral AKT inhibitor under investigation for its therapeutic potential across various oncological indications. As a targeted anti-cancer agent, MIRALUMA's manufacturing process hinges critically on the procurement of high-quality Active Pharmaceutical Ingredient (API). Securing reliable API sources is essential to ensure drug consistency, efficacy, and regulatory compliance, particularly given the intricate synthesis pathways and stringent quality standards associated with oncologic APIs. This article explores the landscape of bulk API sources pertinent to MIRALUMA, emphasizing current suppliers, manufacturing considerations, and strategic procurement insights.

Understanding MIRALUMA API: Chemical and Manufacturing Overview

MIRALUMA's API, miransertib (development code: MK-2206), is a selective allosteric inhibitor of AKT, a serine/threonine kinase pivotal in the PI3K/AKT/mTOR signaling pathway. Its chemical synthesis involves complex multistep processes requiring specific intermediates, reagents, and rigorous purification steps. Exclusive access to high-grade raw materials and stable synthesis pathways are vital for producing consistent API batches that meet Good Manufacturing Practice (GMP) standards.

Global API Supply Landscape

1. Leading API Manufacturers for Oncology Agents

Major generic and innovator pharmaceutical manufacturers possess the capacity to produce AKT inhibitors and related compounds. Most possess comprehensive in-house API synthesis capabilities or established outsourcing arrangements. Key players include:

Pfizer Inc. (original developer of MK-2206): Historically involved in clinical development, with potential licensing or partnership routes for API supply.
Synthesis Contract Manufacturers: Specialized CRO/CDMO companies, such as Lonza, Catalent, and Thermo Fisher Scientific, often provide custom API synthesis for early and late-stage clinical supplies.

2. Contract Development and Manufacturing Organizations (CDMOs)

CDMOs play a pivotal role in API production, offering scalable synthesis, purification, and formulation services that adhere to strict regulatory standards. Notable CDMOs with experience in complex oncology APIs include:

Boehringer-Ingelheim BioXcellence
Patheon (now part of Thermo Fisher Scientific)
Samsung Biologics
Vincellus

These organizations often maintain compliant facilities capable of producing clinical and commercial batches of APIs like miransertib.

3. API Raw Material Suppliers and Intermediates

High-quality raw materials, including specific reagents, solvents, and intermediates, are critical for API synthesis. Reputable raw material suppliers include:

Sigma-Aldrich (Merck Group): Offers a comprehensive portfolio of pharmaceutical-grade intermediates.
Alfa Aesar: Provides specialty chemicals suitable for API synthesis.
Thermo Fisher Scientific: Supplies reagents and raw materials with high purity standards.

Procurement of intermediates directly influences API purity and yield, underscoring the necessity to partner with established suppliers.

Regional and Strategic Considerations

1. North America and Europe

Leading for compliance, quality standards, and regulatory oversight, North American and European API manufacturers are preferred for clinical trial supply and commercial production. Companies in these regions often possess validated manufacturing sites aligned with FDA and EMA regulations, thus minimizing regulatory hurdles.

2. Asia-Pacific

Countries like India and China host numerous API manufacturers with cost advantages and large-scale facilities. Firms such as Sun Pharmaceutical Industries and Hetero Drugs are prominent players. However, due diligence regarding quality standards remains paramount when sourcing from these regions.

3. Emerging Markets and Decentralized Sourcing

Decentralized sourcing strategies can mitigate supply chain risks, facilitate competitive pricing, and allow flexibility during clinical development phases. Establishing dual sourcing agreements with reputable suppliers enhances supply chain resilience.

Evaluating API Suppliers for MIRALUMA

Key criteria for assessing API sources include:

Quality Assurance: GMP certification and adherence to pharmacopeial standards.
Regulatory Compliance: Ability to provide comprehensive documentation and batch records suitable for regulatory submissions.
Supply Stability: Capacity to meet demand forecasts and sustain supply continuity.
Cost and Lead Time: Competitive pricing aligned with project timelines.
Traceability and Transparency: Clear sourcing of raw materials and synthesis processes.

Strategic collaborations with well-established API manufacturers with proven track records in oncology therapeutics are crucial for minimizing development risks.

Emerging Technologies and Innovations in API Supply

Advancements in continuous manufacturing, process intensification, and green chemistry are transforming API synthesis. These innovations can enhance yield, reduce costs, and simplify supply chain logistics.

Process automation reduces variability and improves quality consistency.
Modular manufacturing platforms allow rapid scale-up with minimized lead times.
Improved purification techniques increase API purity levels meeting stringent regulatory standards.

Engaging with vendors leveraging such technologies can offer competitive advantages in API supply for MIRALUMA.

Regulatory Pathways and API Validation

Ensuring API source legitimacy involves comprehensive validation processes, including:

Audit and Qualification: On-site audits, quality audits, and vendor qualification assessments.
Analytical Testing: Confirmation of API identity, potency, purity, and impurity profiles.
Stability and Compatibility Studies: To establish shelf life and compatibility with formulation processes.

Engaging early with regulators and suppliers streamlines the approval process and ensures compliance across all manufacturing stages.

Conclusion

The procurement of bulk API for MIRALUMA necessitates a strategic balance among quality, supply stability, and cost. Leading global CDMOs and established API manufacturers with proven expertise in oncology agents present the most viable sources. Embracing technological innovations in manufacturing and maintaining rigor in supplier qualification can mitigate risks and foster seamless development and commercialization pathways.

Key Takeaways

Robust Vendor Selection: Prioritize GMP-certified suppliers with proven expertise in oncology APIs and regulatory compliance.
Regional Diversification: Minimize supply chain risks by establishing relationships with manufacturers across multiple regions.
Process Modernization: Leverage emerging manufacturing technologies to optimize API quality and scalability.
Regulatory Alignment: Engage in early validation and qualification processes to ensure smooth approval paths.
Supply Chain Resilience: Develop dual sourcing strategies and maintain transparent supplier relationships for consistent API availability.

FAQs

1. What are the primary challenges in sourcing API for MIRALUMA?
Challenges include ensuring high purity and consistency, managing supply chain disruptions, and complying with stringent regulatory standards across different jurisdictions.

2. How do regional differences impact API sourcing?
While North America and Europe offer high-quality standards, costs are often higher. Asia-Pacific regions provide cost-effective options but may require thorough due diligence to ensure quality compliance.

3. Can startups and smaller biotech firms access quality API sources for MIRALUMA development?
Yes, through partnerships with reputable CDMOs and API brokers who specialize in clinical and early commercial supply, assuming rigorous quality verification and regulatory adherence.

4. How does technology influence future API sourcing for therapies like MIRALUMA?
Innovations such as continuous manufacturing and green chemistry enable more efficient, scalable, and sustainable production, reducing lead times and costs.

5. What regulatory considerations should be accounted for in API sourcing?
Manufacturers must provide detailed documentation, validation data, and quality control records compliant with FDA and EMA standards, facilitating smoother approval processes.

References

[1] U.S. Food and Drug Administration. (2021). Guidance for Industry: API Quality with Continuous Manufacturing.
[2] European Medicines Agency. (2022). Guideline on the requirements for quality documentation for starting materials.
[3] ClinicalTrials.gov. (2023). MIRALUMA (miransertib) Clinical Trials Database.
[4] Contract Pharma. (2022). Emerging Trends in API Manufacturing for Oncology Drugs.
[5] PharmSources. (2022). Global API Market Trends and Supplier Directory.

Bulk Pharmaceutical API Sources for MIRALUMA